The New Oral Weight Loss Medication in UAE: How It Differs from Injections
The oral treatment identified in Abu Dhabi’s announcement of 24 April 2026 is Foundayo (orforglipron), a daily GLP-1 receptor agonist. The DoH announcement describes its introduction within the Personalised Weight Management Programme for eligible adults. This does not establish availability or insurance coverage for every patient or clinic.
Quick answer
Abu Dhabi’s April 2026 announcement names Foundayo (orforglipron). A tablet offers a different route, but treatment choice still depends on the exact medicine, eligibility, risks and follow-up.
How does a GLP-1 receptor agonist work?
These medicines act on receptors involved in appetite and glucose regulation. A tablet and an injection can differ in their active ingredient, dosing instructions and approved use. Choosing a daily tablet may suit someone who dislikes injections, while another person may prefer a less frequent schedule. Neither preference proves better adherence or a better medical outcome.
Nutrition remains part of follow-up
If appetite falls, review what you can comfortably eat with the clinical team. Discuss adequate nutrition, hydration, activity suited to your health and symptoms that interfere with eating. A plan can support treatment; it cannot guarantee that muscle loss, deficiencies or side effects will never occur.
Put it into practice: For help turning nutrition goals into daily habits, read how nutrition counselling and coaching can support a practical plan.
Tablets versus injections
Convenience is one consideration, alongside the exact medicine, indication, medical history, side effects and follow-up. Percentages taken from different trials are not a reliable direct comparison when populations, doses and durations differ. This article therefore does not rank all injections above all tablets or promise a particular percentage of weight loss.
What should you verify?
The exact approved product and your eligibility.
The prescribing clinician’s assessment of risks and alternatives.
Current availability, actual price and your own coverage.
A plan for nutrition, physical activity and ongoing review.
Product safety
FDA information on unapproved GLP-1 products explains why a compounded or unapproved product should not be assumed equivalent to an approved medicine. EMA’s Wegovy information concerns a specific product in the EU; it is not evidence of UAE approval for every GLP-1 product.
Educational information, not prescribing advice. This website does not confirm dispensing, stock or treatment eligibility.
Learn more: Explore longer-term nutrition care and follow-up during weight-management treatment.
Frequently Asked Questions (FAQ)
Which oral treatment did Abu Dhabi announce in April 2026?
The 24 April 2026 DoH announcement names Foundayo (orforglipron), introduced within its Personalised Weight Management Programme for eligible adults.
Is a tablet always less effective than an injection?
No general ranking is justified across all products. Compare the exact medicines and relevant trials with the prescriber; percentages from different studies are not a direct head-to-head comparison.
Does the announcement guarantee my insurance coverage or local stock?
No. Check your eligibility, current availability, actual price and coverage with the programme or provider.
Do tablets still have side effects and need follow-up?
Yes. An oral route does not remove medicine-specific risks. The prescriber should explain adverse effects, precautions and follow-up for the exact product.
Nutrition Support Alongside Medical Care
Discuss manageable meals, adequate intake and everyday habits while keeping medicine decisions with your prescribing clinician.
Book a personalised nutrition consultation with Dr. Zeina